236 related articles for article (PubMed ID: 22655512)
21. Corticosteroids in Duchenne muscular dystrophy: a reappraisal.
Wong BL; Christopher C
J Child Neurol; 2002 Mar; 17(3):183-90. PubMed ID: 12026233
[TBL] [Abstract][Full Text] [Related]
22. Old and new therapeutic developments in steroid treatment in Duchenne muscular dystrophy.
Angelini C; Peterle E
Acta Myol; 2012 May; 31(1):9-15. PubMed ID: 22655511
[TBL] [Abstract][Full Text] [Related]
23. Steroid therapy and cardiac function in Duchenne muscular dystrophy.
Markham LW; Spicer RL; Khoury PR; Wong BL; Mathews KD; Cripe LH
Pediatr Cardiol; 2005; 26(6):768-71. PubMed ID: 15990951
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy.
Griggs RC; Miller JP; Greenberg CR; Fehlings DL; Pestronk A; Mendell JR; Moxley RT; King W; Kissel JT; Cwik V; Vanasse M; Florence JM; Pandya S; Dubow JS; Meyer JM
Neurology; 2016 Nov; 87(20):2123-2131. PubMed ID: 27566742
[TBL] [Abstract][Full Text] [Related]
25. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
Gloss D; Moxley RT; Ashwal S; Oskoui M
Neurology; 2016 Feb; 86(5):465-72. PubMed ID: 26833937
[TBL] [Abstract][Full Text] [Related]
26. Corticosteroid Treatments in Males With Duchenne Muscular Dystrophy: Treatment Duration and Time to Loss of Ambulation.
Kim S; Campbell KA; Fox DJ; Matthews DJ; Valdez R;
J Child Neurol; 2015 Sep; 30(10):1275-80. PubMed ID: 25414237
[TBL] [Abstract][Full Text] [Related]
27. Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients.
Rice ML; Wong B; Horn PS; Yang MB
J AAPOS; 2018 Jun; 22(3):192-196. PubMed ID: 29733899
[TBL] [Abstract][Full Text] [Related]
28. Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy.
Matthews DJ; James KA; Miller LA; Pandya S; Campbell KA; Ciafaloni E; Mathews KD; Miller TM; Cunniff C; Meaney FJ; Druschel CM; Romitti PA; Fox DJ;
J Child Neurol; 2010 Nov; 25(11):1319-24. PubMed ID: 20207610
[TBL] [Abstract][Full Text] [Related]
29. Deflazacort for the treatment of Duchenne Dystrophy: a systematic review.
Campbell C; Jacob P
BMC Neurol; 2003 Sep; 3():7. PubMed ID: 12962544
[TBL] [Abstract][Full Text] [Related]
30. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management.
Moxley RT; Pandya S; Ciafaloni E; Fox DJ; Campbell K
J Child Neurol; 2010 Sep; 25(9):1116-29. PubMed ID: 20581335
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Outcome of Interdisciplinary Management of Patients with Duchenne Muscular Dystrophy Receiving Daily Glucocorticoid Treatment.
Wong BL; Rybalsky I; Shellenbarger KC; Tian C; McMahon MA; Rutter MM; Sawnani H; Jefferies JL
J Pediatr; 2017 Mar; 182():296-303.e1. PubMed ID: 28043681
[TBL] [Abstract][Full Text] [Related]
32. Quadriceps muscle strength in Duchenne muscular dystrophy and effect of corticosteroid treatment.
Merlini L; Cecconi I; Parmeggiani A; Cordelli DM; Dormi A
Acta Myol; 2020 Dec; 39(4):200-206. PubMed ID: 33458575
[TBL] [Abstract][Full Text] [Related]
33. A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy.
Bonifati MD; Ruzza G; Bonometto P; Berardinelli A; Gorni K; Orcesi S; Lanzi G; Angelini C
Muscle Nerve; 2000 Sep; 23(9):1344-7. PubMed ID: 10951436
[TBL] [Abstract][Full Text] [Related]
34. Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy.
Biggar WD; Skalsky A; McDonald CM
J Neuromuscul Dis; 2022; 9(4):463-476. PubMed ID: 35723111
[TBL] [Abstract][Full Text] [Related]
35. A Review of Deflazacort for Patients With Duchenne Muscular Dystrophy.
Bylo M; Farewell R; Coppenrath VA; Yogaratnam D
Ann Pharmacother; 2020 Aug; 54(8):788-794. PubMed ID: 32019318
[No Abstract] [Full Text] [Related]
36. Fractures and Linear Growth in a Nationwide Cohort of Boys With Duchenne Muscular Dystrophy With and Without Glucocorticoid Treatment: Results From the UK NorthStar Database.
Joseph S; Wang C; Bushby K; Guglieri M; Horrocks I; Straub V; Ahmed SF; Wong SC;
JAMA Neurol; 2019 Jun; 76(6):701-709. PubMed ID: 30855644
[TBL] [Abstract][Full Text] [Related]
37. Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.
Shieh PB; Mcintosh J; Jin F; Souza M; Elfring G; Narayanan S; Trifillis P; Peltz SW; Mcdonald CM; Darras BT;
Muscle Nerve; 2018 Nov; 58(5):639-645. PubMed ID: 30028519
[TBL] [Abstract][Full Text] [Related]
38. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.
King WM; Ruttencutter R; Nagaraja HN; Matkovic V; Landoll J; Hoyle C; Mendell JR; Kissel JT
Neurology; 2007 May; 68(19):1607-13. PubMed ID: 17485648
[TBL] [Abstract][Full Text] [Related]
39. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
[TBL] [Abstract][Full Text] [Related]
40. A 19-year-old ambulant Duchenne patient with stunted growth on long-term corticosteroids.
Merlini L
Neuromuscul Disord; 2014 May; 24(5):417-8. PubMed ID: 24631208
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]